OKYO Pharma (Nasdaq: OKYO) will participate in the virtual BTIG Biotechnology Conference 2026 on July 28-29, 2026. Company representatives will include CEO Robert J. Dempsey, CFO Keeren Shah, and CMO Flavio Mantelli.
The company is a clinical-stage biopharmaceutical developer of therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. According to OKYO Pharma, it plans to initiate a global Phase 3 pivotal trial in the second half of this year, enrolling about 111 patients to evaluate a single-dose regimen of urcosimod for NCP.
The conference will feature virtual 1:1 meetings, which can be scheduled through a BTIG representative. Additional corporate and contact information is available on OKYO Pharma’s website and through its business development and investor relations contact.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – OKYO
+5.81%
4 alerts
+5.81%Session close to close
+9.8%Peak Tracked
$81.34MMarket Cap
0.6xRel. Volume
In the Jul 27 session, OKYO gained 5.81%, reflecting a notable positive market reaction.
Argus tracked a peak move of +9.8% during that session.
Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
The stock moved +5.8% in the session following this news. Historical event 1085287 recorded a 5.56% ...
Analysis
The stock moved +5.8% in the session following this news. Historical event 1085287 recorded a 5.56% 24-hour reaction. The BTIG participation notice can be assessed against that precedent, while an effective F-3 shelf dated February 2, 2026 permits up to $200,000,000, a financing-related risk.
"developing investigational therapies for the treatment of neuropathic corneal pain"
Neuropathic corneal pain is chronic, often severe eye pain caused by damage or malfunction in the tiny nerves of the cornea, where the eye surface can feel burning, stinging, or like something is in it despite little visible damage. It matters to investors because it represents a persistent, hard-to-treat medical need that drives demand for new drugs, diagnostics, devices and regulatory approvals, similar to how fixing a frayed electrical wire stops false alarm signals.
phase 3medical
"initiate a global Phase 3 pivotal clinical trial"
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
pivotal clinical trialmedical
"initiate a global Phase 3 pivotal clinical trial"
A pivotal clinical trial is a late-stage medical study designed to provide the main evidence regulators use to decide whether a drug or medical device can be approved and sold; think of it as the product’s final exam. For investors, the trial’s outcome is critical because a clear pass can unlock regulatory approval, market access and future revenue, while failure can halt commercialization and materially affect a company’s valuation.
single-dose regimenmedical
"enrolling approximately 111 patients to evaluate a single-dose regimen"
A single-dose regimen is a treatment plan in which a medication or vaccine is administered just once to produce the intended protective or therapeutic effect, rather than through multiple injections or pills over days or weeks. It matters to investors because single-dose products can simplify distribution, lower treatment costs, improve patient adherence, and change market demand and regulatory review timelines—much like a one-time purchase versus an ongoing subscription.
LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced its participation in the BTIG Biotechnology Conference 2026 taking place virtually on July 28-29, 2026.
Company Participation: Robert J. Dempsey, Chief Executive Officer, Keeren Shah, Chief Financial Officer, Flavio Mantelli MD, PhD, Chief Medical Officer
Date/Time: July 28-29, 2026
Location: Virtual
1:1 Meetings: schedule a one-on-one meeting with management by contacting your BTIG representative
About OKYOPharma OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.
OKYO Pharma Ltd Paul Spencer Business Development and Investor Relations +44 (0) 207 495 2379 Email: info@okyopharma.com
FAQ
When will OKYO Pharma (NASDAQ: OKYO) participate in the BTIG Biotechnology Conference 2026?
OKYO Pharma will participate in the BTIG Biotechnology Conference 2026 on July 28-29, 2026. According to OKYO Pharma, the event will be held virtually and will include 1:1 investor meetings with senior management, accessible by contacting a BTIG representative.
Which OKYO Pharma executives will attend the BTIG Biotechnology Conference 2026?
OKYO Pharma will be represented by CEO Robert J. Dempsey, CFO Keeren Shah, and CMO Flavio Mantelli. According to OKYO Pharma, these senior leaders will be available for virtual one-on-one meetings with investors during the July 28-29, 2026 BTIG Biotechnology Conference.
How can investors schedule 1:1 meetings with OKYO Pharma at the BTIG Biotechnology Conference 2026?
Investors can schedule 1:1 meetings with OKYO Pharma’s management by contacting their BTIG representative. According to OKYO Pharma, these meetings will be held virtually during the July 28-29, 2026 conference, providing direct access to the company’s executive and clinical leadership team.
What does OKYO Pharma (OKYO) focus on in its clinical development pipeline?
OKYO Pharma focuses on developing therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. According to OKYO Pharma, its lead efforts include a planned global Phase 3 pivotal trial evaluating a single-dose regimen of urcosimod for the treatment of NCP.
When will OKYO Pharma start its Phase 3 trial of urcosimod for neuropathic corneal pain?
OKYO Pharma plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year. According to OKYO Pharma, the study will enroll approximately 111 patients to evaluate a single-dose regimen of urcosimod for neuropathic corneal pain (NCP).
On which exchange is OKYO Pharma listed and what is its stock symbol?
OKYO Pharma’s ordinary shares trade on the Nasdaq Capital Market under the stock symbol OKYO. According to OKYO Pharma, it is a clinical-stage biopharmaceutical company developing investigational therapies for neuropathic corneal pain and anterior segment eye diseases.
